Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix

Table 2 Multivariate analysis of PALN recurrence

Parameters	Number	Hazard ratio (95% CI)	p value
Age			0.233
< 50	58	reference
50-60	59	--	0.124
> 60	71	--	0.141
Stage			0.831
I	22	reference
II	145	--	0.852
III-IVA	41	--	0.686
Parametrial score			0.056
0	36	reference
1-3	103	--	0.749
4-6	49	--	0.222
Tumor size (cm)			0.333
≤ 5.0	48	reference
> 5.0	53		0.304
unknown	87		0.836
Positive pelvic node		--	0.170
Hemoglobin < 12 g/dL		--	0.525
Smoking		--	0.484
Field size (< 18 cm)		--	0.959
Pretreatment CEA level (ng/mL)			0.005
< 5	149	reference
5-10	16	1.007 (0.232-4.365)	0.993
≥ 10	23	4.206 (1.801-9.821)	0.001
Pretreatment SCC-Ag level (ng/mL)			< 0.001
< 10	128	reference
10-40	42	2.617 (1.180-5.804)	0.018
≥ 40	18	6.851 (2.722-16.935)	< 0.001

Abbreviations: CI = confidence interval; SCC-Ag = squamous cell carcinoma antigen; CEA = Carcinoembryonic antigen

ISSN: 1748-717X